Tvardi Therapeutics, Inc. (TVRD)
NASDAQ: TVRD · Real-Time Price · USD
3.190
+0.150 (4.93%)
At close: Apr 28, 2026, 4:00 PM EDT
3.200
+0.010 (0.31%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Tvardi Therapeutics Stock Forecast
TVRD's stock price has decreased by -83.4% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Tvardi Therapeutics stock have an average target of 29.5, with a low estimate of 3.00 and a high estimate of 65. The average target predicts an increase of 824.76% from the current stock price of 3.19.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Tvardi Therapeutics stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 4 | 4 | 4 | 4 | 4 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Hold → Sell Downgrades $4 → $3 | Hold → Sell | Downgrades | $4 → $3 | -5.96% | Apr 20, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +370.22% | Apr 1, 2026 |
| Barclays | Barclays | Hold Maintains $5 → $4 | Hold | Maintains | $5 → $4 | +25.39% | Apr 1, 2026 |
| Piper Sandler | Piper Sandler | Hold Maintains $4 → $3 | Hold | Maintains | $4 → $3 | -5.96% | Apr 1, 2026 |
| Raymond James | Raymond James | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Oct 14, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.50
from -3.26
EPS Next Year
-2.78
from -2.50
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.68 | -0.97 | ||||||
| Avg | -2.50 | -2.78 | ||||||
| Low | -3.25 | -4.33 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.